We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Azelaic Acid Versus Hydroquinone in Melasma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00927771
Recruitment Status : Unknown
Verified June 2009 by Callender Center for Clinical Research.
Recruitment status was:  Recruiting
First Posted : June 25, 2009
Last Update Posted : June 25, 2009
Information provided by:

June 23, 2009
June 25, 2009
June 25, 2009
June 2009
June 2010   (Final data collection date for primary outcome measure)
Improvement of melasma [ Time Frame: 6 months ]
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
Azelaic Acid Versus Hydroquinone in Melasma
Efficacy & Safety of Azelaic Acid 15% Gel vs. Hydroquinone 4% Cream in the Treatment of Melasma
The purpose of this study is to compare the safety and effectiveness of Azelaic Acid Gel to Hydroquinone Cream in the treatment of melasma.
Melasma is a chronic condition in which dark areas appear on the forehead, cheeks, and upper lips. Hydroquinone is a skin lightener (or fade cream) and is one of the most commonly used medications for the treatment of melasma. Azelaic acid gel is currently used to treat acne and rosacea.
Phase 4
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
  • Drug: azelaic acid gel
    azelaic acid 15% gel twice a day for 6 months
    Other Name: Finacea Gel
  • Drug: hydroquinone cream
    hydroquinone 4% cream twice a day for 6 months
    Other Names:
    • Claripel
    • Lustra
  • Experimental: Azelaic Acid
    Intervention: Drug: azelaic acid gel
  • Active Comparator: Hydroquinone
    Intervention: Drug: hydroquinone cream
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Unknown status
December 2010
June 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • must have stable moderate-severe epidermal or mixed melasma involving the face
  • all races
  • males and females
  • persons taking birth control medication, hormone replacement therapy or any other hormone altering medication may participate only if they have not started or stopped the medication within the last 3 months

Exclusion Criteria:

  • if the person has only dermal melasma
  • pregnancy, breastfeeding, a positive pregnancy test in the office or plans to become pregnant
  • a known allergy or sensitivity ot azelaic acid or hydroquinone
  • the use of photosensitizing medications (ex. tetracycline) within 3 months of the study.
  • starting or stopping hormonal medication within 3 months
  • chemical peels, microdermabrasion, or laser treatment within 6 months
  • worsening or improving melasma
Sexes Eligible for Study: All
18 Years to 89 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Valerie D. Callender, MD, Callender Center for Clinical Research
Callender Center for Clinical Research
Not Provided
Principal Investigator: Valerie D Callender, MD Howard University
Callender Center for Clinical Research
June 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP